2024
Procházková, Jiřina; Fedr, Radek; Hradilová, Barbora; Kvokačková, Barbora; Slavík, Josef; Kováč, Ondrej; Machala, Miroslav; Fabian, Pavel; Navrátil, Jiří; Kráčalíková, Simona; Levková, Monika; Ovesná, Petra; Bouchal, Jan; Souček, Karel
In: Journal of lipid research, vol. 65, no. 9, pp. 100609, 2024, ISSN: 1539-7262 0022-2275, (Place: United States).
Abstract | Links | BibTeX | Tags: *Breast Neoplasms/metabolism/pathology, *Epithelial-Mesenchymal Transition, *Glycosphingolipids/metabolism/analysis, *Single-Cell Analysis/methods, Breast cancer, Epithelial Cells, Female, Glycosphingolipids, Humans, Phenotype, phenotypic plasticity, stromal-like cells, surface profiling
@article{prochazkova_single-cell_2024,
title = {Single-cell profiling of surface glycosphingolipids opens a new dimension for deconvolution of breast cancer intratumoral heterogeneity and phenotypic plasticity.},
author = {Jiřina Procházková and Radek Fedr and Barbora Hradilová and Barbora Kvokačková and Josef Slavík and Ondrej Kováč and Miroslav Machala and Pavel Fabian and Jiří Navrátil and Simona Kráčalíková and Monika Levková and Petra Ovesná and Jan Bouchal and Karel Souček},
doi = {10.1016/j.jlr.2024.100609},
issn = {1539-7262 0022-2275},
year = {2024},
date = {2024-09-01},
journal = {Journal of lipid research},
volume = {65},
number = {9},
pages = {100609},
abstract = {Glycosylated sphingolipids (GSLs) are a diverse group of cellular lipids typically reported as being rare in normal mammary tissue. In breast cancer (BCa), GSLs have emerged as noteworthy markers associated with breast cancer stem cells, mediators of phenotypic plasticity, and contributors to cancer cell chemoresistance. GSLs are potential surface markers that can uniquely characterize the heterogeneity of the tumor microenvironment, including cancer cell subpopulations and epithelial-mesenchymal plasticity (EMP). In this study, mass spectrometry analyses of the total sphingolipidome in breast epithelial cells and their mesenchymal counterparts revealed increased levels of Gb3 in epithelial cells and significantly elevated GD2 levels in the mesenchymal phenotype. To elucidate if GSL-related epitopes on BCa cell surfaces reflect EMP and cancer status, we developed and rigorously validated a 12-color spectral flow cytometry panel. This panel enables the simultaneous detection of native GSL epitopes (Gb3, SSEA1, SSEA3, SSEA4, and GD2), epithelial-mesenchymal transition markers (EpCAM, TROP2, and CD9), and lineage markers (CD45, CD31, and CD90) at the single-cell level. Next, the established panel was used for the analysis of BCa primary tumors and revealed surface heterogeneity in SSEA1, SSEA3, SSEA4, GD2, and Gb3, indicative of native epitope presence also on non-tumor cells. These findings further highlighted the phenotype-dependent alterations in GSL surface profiles, with differences between epithelial and stromal cells in the tumor. This study provides novel insights into BCa heterogeneity, shedding light on the potential of native GSL-related epitopes as markers for EMP and cancer status in fresh clinical samples. The developed single-cell approach offers promising avenues for further exploration.},
note = {Place: United States},
keywords = {*Breast Neoplasms/metabolism/pathology, *Epithelial-Mesenchymal Transition, *Glycosphingolipids/metabolism/analysis, *Single-Cell Analysis/methods, Breast cancer, Epithelial Cells, Female, Glycosphingolipids, Humans, Phenotype, phenotypic plasticity, stromal-like cells, surface profiling},
pubstate = {published},
tppubtype = {article}
}
Glycosylated sphingolipids (GSLs) are a diverse group of cellular lipids typically reported as being rare in normal mammary tissue. In breast cancer (BCa), GSLs have emerged as noteworthy markers associated with breast cancer stem cells, mediators of phenotypic plasticity, and contributors to cancer cell chemoresistance. GSLs are potential surface markers that can uniquely characterize the heterogeneity of the tumor microenvironment, including cancer cell subpopulations and epithelial-mesenchymal plasticity (EMP). In this study, mass spectrometry analyses of the total sphingolipidome in breast epithelial cells and their mesenchymal counterparts revealed increased levels of Gb3 in epithelial cells and significantly elevated GD2 levels in the mesenchymal phenotype. To elucidate if GSL-related epitopes on BCa cell surfaces reflect EMP and cancer status, we developed and rigorously validated a 12-color spectral flow cytometry panel. This panel enables the simultaneous detection of native GSL epitopes (Gb3, SSEA1, SSEA3, SSEA4, and GD2), epithelial-mesenchymal transition markers (EpCAM, TROP2, and CD9), and lineage markers (CD45, CD31, and CD90) at the single-cell level. Next, the established panel was used for the analysis of BCa primary tumors and revealed surface heterogeneity in SSEA1, SSEA3, SSEA4, GD2, and Gb3, indicative of native epitope presence also on non-tumor cells. These findings further highlighted the phenotype-dependent alterations in GSL surface profiles, with differences between epithelial and stromal cells in the tumor. This study provides novel insights into BCa heterogeneity, shedding light on the potential of native GSL-related epitopes as markers for EMP and cancer status in fresh clinical samples. The developed single-cell approach offers promising avenues for further exploration.
2016
Simkova, Dana; Kharaishvili, Gvantsa; Korinkova, Gabriela; Ozdian, Tomas; Suchánková-Kleplová, Tereza; Soukup, Tomas; Krupka, Michal; Galandakova, Adela; Dzubak, Petr; Janikova, Maria; Navratil, Jiri; Kahounova, Zuzana; Soucek, Karel; Bouchal, Jan
The dual role of asporin in breast cancer progression. Journal Article
In: Oncotarget, vol. 7, no. 32, pp. 52045–52060, 2016, ISSN: 1949-2553, (Place: United States).
Abstract | Links | BibTeX | Tags: 3D cultivation, asporin, Breast cancer, Breast Neoplasms/metabolism/mortality/*pathology, Disease-Free Survival, Extracellular Matrix Proteins/*metabolism, Female, Fibroblasts/metabolism/pathology, grade, Humans, Kaplan-Meier Estimate, Prognosis, stiffness, Tumor Microenvironment/physiology
@article{simkova_dual_2016,
title = {The dual role of asporin in breast cancer progression.},
author = {Dana Simkova and Gvantsa Kharaishvili and Gabriela Korinkova and Tomas Ozdian and Tereza Suchánková-Kleplová and Tomas Soukup and Michal Krupka and Adela Galandakova and Petr Dzubak and Maria Janikova and Jiri Navratil and Zuzana Kahounova and Karel Soucek and Jan Bouchal},
doi = {10.18632/oncotarget.10471},
issn = {1949-2553},
year = {2016},
date = {2016-08-01},
journal = {Oncotarget},
volume = {7},
number = {32},
pages = {52045–52060},
abstract = {Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer. According to our in silico search, high asporin expresion associates with significantly better relapse free survival (RFS) in patients with low-grade tumors but RFS is significantly worse in patients with grade 3 tumors. In line with other studies, we have confirmed asporin expression by RNA scope in situ hybridization in cancer associated fibroblasts. We have also found asporin expression in the Hs578T breast cancer cell line which we confirmed by quantitative RT-PCR and western blotting. From multiple testing, we found that asporin can be downregulated by bone morphogenetic protein 4 while upregulation may be facilited by serum-free cultivation or by three dimensional growth in stiff Alvetex scaffold. Downregulation by shRNA inhibited invasion of Hs578T as well as of CAFs and T47D cells. Invasion of asporin-negative MDA-MB-231 and BT549 breast cancer cells through collagen type I was enhanced by recombinant asporin. Besides other investigations, large scale analysis of aspartic acid repeat polymorphism will be needed for clarification of the asporin dual role in progression of breast cancer.},
note = {Place: United States},
keywords = {3D cultivation, asporin, Breast cancer, Breast Neoplasms/metabolism/mortality/*pathology, Disease-Free Survival, Extracellular Matrix Proteins/*metabolism, Female, Fibroblasts/metabolism/pathology, grade, Humans, Kaplan-Meier Estimate, Prognosis, stiffness, Tumor Microenvironment/physiology},
pubstate = {published},
tppubtype = {article}
}
Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer. According to our in silico search, high asporin expresion associates with significantly better relapse free survival (RFS) in patients with low-grade tumors but RFS is significantly worse in patients with grade 3 tumors. In line with other studies, we have confirmed asporin expression by RNA scope in situ hybridization in cancer associated fibroblasts. We have also found asporin expression in the Hs578T breast cancer cell line which we confirmed by quantitative RT-PCR and western blotting. From multiple testing, we found that asporin can be downregulated by bone morphogenetic protein 4 while upregulation may be facilited by serum-free cultivation or by three dimensional growth in stiff Alvetex scaffold. Downregulation by shRNA inhibited invasion of Hs578T as well as of CAFs and T47D cells. Invasion of asporin-negative MDA-MB-231 and BT549 breast cancer cells through collagen type I was enhanced by recombinant asporin. Besides other investigations, large scale analysis of aspartic acid repeat polymorphism will be needed for clarification of the asporin dual role in progression of breast cancer.